Bridging Anticoagulation with Mechanical Heart Valves: Current Guidelines and Clinical Decisions.
Mahboob AliRichard C BeckerPublished in: Current cardiology reports (2020)
Randomized, controlled trials are not available; yet, there is a wealth of experience to guide best practice. Current guidelines represent a compilation of data from trials of atrial fibrillation and expert opinion. Results from the PERI-OP trial of patients with either a mechanical heart valve, atrial fibrillation, or atrial flutter requiring interruption of oral anticoagulant therapy for surgery will inform clinical practice. Patient-specific factors and valve-specific factors are paramount when deciding whether a period of anticoagulant therapy interruption is safe. Similarly, the safety and efficacy of bridging anticoagulant therapy and the optimal time after surgery for restarting oral anticoagulants is vital to optimal patient care.
Keyphrases
- atrial fibrillation
- oral anticoagulants
- clinical practice
- aortic valve
- catheter ablation
- left atrial
- left atrial appendage
- direct oral anticoagulants
- heart failure
- mitral valve
- randomized controlled trial
- percutaneous coronary intervention
- aortic stenosis
- minimally invasive
- healthcare
- primary care
- transcatheter aortic valve replacement
- study protocol
- aortic valve replacement
- clinical trial
- coronary artery bypass
- venous thromboembolism
- electronic health record
- quality improvement
- stem cells
- left ventricular
- mesenchymal stem cells
- transcatheter aortic valve implantation
- phase ii
- machine learning
- big data
- surgical site infection
- smoking cessation